Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NMBR | P28336 | 3/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880943 | 0.82 | ACHE (0.44) | TACR1BCHEACHESIGMAR1KMT2A | |
| SCHEMBL5880984 | 0.80 | ACHE (0.40) | TACR1BCHEACHESIGMAR1GRIN2B | |
| SCHEMBL5880978 | 0.78 | KMT2A (0.52) | ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL5880988 | 0.77 | ACHE (0.38) | TACR1BCHEACHENMBRSIGMAR1 | |
| SCHEMBL5881006 | 0.74 | ALDH1A1 (0.39) | ALDH1A1L3MBTL1KMT2A | |
| SCHEMBL5881132 | 0.72 | NMBR (0.42) | TACR1NMBR | |
| SCHEMBL5881279 | 0.72 | NMBR (0.42) | TACR1NMBR | |
| SCHEMBL5881058 | 0.72 | NMBR (0.40) | TACR1NMBRSIGMAR1 | |
| SCHEMBL5881213 | 0.72 | NMBR (0.40) | TACR1NMBRSIGMAR1 | |
| SCHEMBL6609995 | 0.72 | ACHE (0.43) | TACR1BCHEACHESIGMAR1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | claimed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | claimed |
| US-7122570-B2 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2006-10-17 | — | — | US | disclosed |
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | ZENTARIS AG (DE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232873-A1 | Tetrahydrocarbazol derivatives as ligands for G-protein-coupled receptors (GPCR) | GPR4, GPR88, GPR35 | TACR1 300/4885BCHE 2233/4885ACHE 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.